Cutler Group LP Biocryst Pharmaceuticals Inc Transaction History

Cutler Group LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$7.89 - $17.88 $55,600 - $126,000	-7,047 Reduced 83.0%	1,443 $15,000
Q1 2022 Apr 14, 2022	BUY	$11.56 - $19.76 $26,287 - $44,934	2,274 Added 36.58%	8,490 $138,000
Q4 2021 Jan 18, 2022	SELL	$11.18 - $15.46 $188,315 - $260,408	-16,844 Reduced 73.04%	6,216 $86,000
Q3 2021 Oct 26, 2021	BUY	$14.21 - $17.65 $215,423 - $267,574	15,160 Added 191.9%	23,060 $331,000
Q2 2021 Jul 19, 2021	BUY	$9.5 - $17.24 $75,050 - $136,196	7,900 New	7,900 $124,000
Q3 2019 Oct 28, 2019	SELL	$2.5 - $3.73 $6,000 - $8,952	-2,400 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$2.91 - $9.15 $5,529 - $17,385	-1,900 Reduced 44.19%	2,400 $9,000
Q1 2019 May 10, 2019	BUY	$7.38 - $9.72 $30,258 - $39,852	4,100 Added 2050.0%	4,300 $35,000
Q3 2018 Nov 07, 2018	SELL	$5.52 - $7.99 $2,760 - $3,995	-500 Reduced 71.43%	200 $1,000
Q2 2018 Aug 10, 2018	BUY	$4.6 - $6.52 $2,300 - $3,260	500 Added 250.0%	700 $4,000
Q1 2018 May 11, 2018	BUY	$4.35 - $5.82 $434 - $582	100 Added 100.0%	200 $0
Q4 2017 Jan 17, 2018	SELL	$4.16 - $5.33 $34,661 - $44,409	-8,332 Reduced 98.81%	100 $0
Q3 2017 Oct 17, 2017	BUY	$4.1 - $5.97 $34,571 - $50,339	8,432	8,432 $44,000

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.45B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.